Status: Recruiting
Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T
A multicenter, open-label, prospective study to investigate immune boost response changes in patients with metastatic castrate-resistant prostate cancer (mCRPC).
Participants needed: 400
Trial details
Phase: Phase 2Age: 18+Biological sex: MaleType: InterventionalSponsor: DendreonUpdated: Aug 27, 2025Locations: 31
Eligibility criteria
Potential subjects are men aged ≥18 years who are clinically indicated for treat... [+4]
Men who are not clinically indicated for treatment with PROVENGE® (asymptomatic... [+3]